DanCann Pharma A/S
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company's development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 Cann… Read more
DanCann Pharma A/S (DCPXF) - Total Liabilities
Latest total liabilities as of December 2024: $1.49 Million USD
Based on the latest financial reports, DanCann Pharma A/S (DCPXF) has total liabilities worth $1.49 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DanCann Pharma A/S - Total Liabilities Trend (2019–2024)
This chart illustrates how DanCann Pharma A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
DanCann Pharma A/S Competitors by Total Liabilities
The table below lists competitors of DanCann Pharma A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
Taiwan | NT$77.78 Million |
|
AB Science S.A
PINK:ABSCF
|
USA | $48.54 Million |
|
Eusu Holdings
KO:000700
|
Korea | ₩66.81 Billion |
|
NGL Fine-Chem Limited
NSE:NGLFINE
|
India | ₹1.84 Billion |
|
DarioHealth Corp
NASDAQ:DRIO
|
USA | $42.79 Million |
|
Black Mammoth Metals Corporation
PINK:LQRCF
|
USA | $336.15K |
|
Brinova Fastigheter AB (publ)
ST:BRIN-B
|
Sweden | Skr12.22 Billion |
|
Bon Fame Co Ltd
TWO:8433
|
Taiwan | NT$2.45 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down DanCann Pharma A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DanCann Pharma A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DanCann Pharma A/S (2019–2024)
The table below shows the annual total liabilities of DanCann Pharma A/S from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | $1.49 Million | -81.10% |
| 2023-09-30 | $7.89 Million | -27.65% |
| 2022-09-30 | $10.90 Million | -30.22% |
| 2021-09-30 | $15.62 Million | +198.97% |
| 2020-09-30 | $5.23 Million | +149.11% |
| 2019-09-30 | $2.10 Million | -- |